Investing.com — Johnson & Johnson (NYSE:), a global healthcare company, is reportedly in discussions to acquire Intra-Cellular Therapies (NASDAQ:) Inc., a biopharmaceutical firm specializing in therapies for central nervous system disorders. This rumor was cuirculated by Bloomberg, who cited anonymous sources familiar with the matter.
The acquisition could potentially be finalized within this week, as per the anonymous sources. However, it’s important to note that while these negotiations are ongoing, they might not necessarily result in a deal. The possibility of other interested parties emerging cannot be ruled out either.
Intra-Cellular Therapies Inc. has seen a significant increase in its stock value over the past year, with an approximate rise of 40%. This surge has brought the company’s market value to an estimated $10 billion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Source link
